Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancerJonathan Anker, Sumanta K Pal, Seunghee Kim-Schulze, Huan Wang, Rebecca Halperin, Andrew Uzilov, Naoko Imai, Shingo Eikawa, Takuro Saito, Robert Sebra, Noah M Hahn, Manishkumar Patel, Jingjing Qi, Hui Xie, Nina BhardwajSee the full list of authors
22 August 2023
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapyHua Zhong, Xueyan Zhang, Panwen Tian, Tianqing Chu, Qisen Guo, Xinmin Yu, Zhuang Yu, Yalun Li, Lijuan Chen, Jie Liu, Yan Zhang, Yan Guan, Xun Shi, Jing Wang, Yanqiu ZhaoSee the full list of authors
18 August 2023
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinomaNeslihan Arife Kaya, David Tai, Xinru Lim, Jia Qi Lim, Mai Chan Lau, Denise Goh, Cheryl Zi Jin Phua, Felicia Yu Ting Wee, Craig Ryan Joseph, Jeffrey Chun Tatt Lim, Zhen Wei Neo, Jiangfeng Ye, Lawrence Cheung, Joycelyn Lee, Kelvin S H LokeSee the full list of authors
16 August 2023
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expressionKristan Meetze, Naveen K Mehta, Bochong Li, Jennifer S Michaelson, Patrick A Baeuerle
16 August 2023
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastomaChristopher Cultrara, Christopher Uhl, Kenneth Kirby, Essam Abed Elrazaq, Amelia Zellander, David W Andrews, Charles B Scott, Lorenzo Galluzzi, Mark A Exley, Jenny Zilberberg
7 August 2023
Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trialMichelle V Dietz, Katrien L A Quintelier, Job P van Kooten, Nadine L de Boer, Madelief Vink, Alexandra R M Brandt-Kerkhof, Cornelis Verhoef, Yvan Saeys, Joachim G J V Aerts, Marcella Willemsen, Sofie Van Gassen, Eva V E Madsen
3 August 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, Anne E O’Shea, Patrick McCarthy, Robert Connor Chick, Guy Travis Clifton, Timothy Vreeland, Franklin A Valdera, Ankur Tiwari, Diane Hale, Phillip Kemp Bohan, Annelies Hickerson, Todd Smolinsky, Katryna ThomasSee the full list of authors
3 August 2023
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient recordsMathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chrétien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Gonçalves, Aaron E LisbergSee the full list of authors
3 August 2023
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neckJennifer M Johnson, Ioannis A Vathiotis, Larry A Harshyne, Ayesha Ali, Voichita Bar Ad, Rita Axelrod, Emily Lorber, Joseph Curry, David M Cognetti, Adam J Luginbuhl, Madalina Tuluc, Scott Keith, Mỹ G Mahoney, Athanassios Argiris
3 August 2023
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II studyMasato Karayama, Naoki Inui, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Kazuhiro Asada, Tomohiro Uto, Masato Fujii, Takashi Matsui, Shun Matsuura, Dai HashimotoSee the full list of authors
27 July 2023
